The WHO has classed this outbreak as “extraordinary” due to the lack of therapeutic options and epidemiological trends.

Boehringer Ingelheim has received Japan’s MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF.

The wider US HHS is going through a leadership upheaval, as Republicans aim to keep voters on side amid the looming midterm elections.

ITALVACUUM will participate in EXPOQUIMIA 2026, taking place in Barcelona from 2 to 5 June, where the company will present its vacuum drying technologies developed for pharmaceutical and ...

Ovarian cancer research is entering a pivotal era characterized by increasing complexity for large, global studies.

The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.

Agreement on the proposed Critical Medicines Act (CMA) represents an important step for boosting the EU pharma sector.

An indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer’s tafamidis in frontline ATTR-CM.

Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

Coya Therapeutics has received fast track designation from the US FDA for COYA 302, an investigational biologic combination therapy to treat ALS.

Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.

AstraZeneca’s Imfinzi (durvalumab) will become the first immunotherapy available for UK National Health Service (NHS) patients with an aggressive form of stomach cancer, after a ...